Organigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit Facilities

The most recent release dated 2026-04-15 confirms the closing of three previously announced transactions that were integral to Organigram's strategic pivot into European markets. - Acquisition Closing: Organigram closed the acquisition of Sanity Group GmbH (Germany) for an upfront consideration of €107.3 million (€78.0 million cash, €29.3 million in shares). - Private Placement: Simultaneously closed a C$65.2 million private placement with BT DE Investments Inc. (subsidiary of British American Tobacco - BAT), consisting of common and non-voting Class A convertible preferred shares at C$3.00 per share. - Credit Facilities: Finalized senior secured credit facilities totaling up to C$60 million with ATB Financial, including a term facility, revolving credit, and operating facility. - Earnout Structure: Sellers are entitled to up to €113.8 million in contingent consideration based on Sanity Group's financial performance through April 1, 2027, subject to share price floors/caps (C$3.00 floor / C$4.00 cap).

This news serves as the execution confirmation of deals announced in February 2026 and approved by shareholders in March 2026. It removes regulatory and closing uncertainty but does not introduce new financial terms or strategic direction beyond what was previously disclosed to the market.

• Routine Nature: The transaction details (price, structure, financing sources) were fully disclosed on February 18, 2026, and approved by shareholders on March 30, 2026. The April 15 announcement is a procedural confirmation of closing conditions met. Under the definition provided, if the market already knew about it, it is routine.
• Positive Execution: Closing removes execution risk associated with regulatory approvals (FDI clearance) and financing contingencies. It validates management's ability to execute large-scale M&A.
• Dilution Concerns: The BAT investment involves convertible preferred shares where the conversion rate increases by 7.5% per annum until ownership reaches a 49% threshold. This is aggressive dilution protection for the strategic investor, potentially negative for existing common shareholders if performance targets are met and conversions accelerate.
• Valuation Context: The deal was priced at C$3.00 per share (a premium to the pre-announcement price of ~C$1.75 in Feb 2026). However, the stock is currently trading near $1.98 (April 14), significantly below the issue price of the new financing ($3.00). This suggests the market remains skeptical about the accretive nature or integration risks despite the closing.
• Debt Load: The company has taken on C$60 million in senior secured debt. While manageable given cash flow improvements (Q1 FY2026 Adjusted EBITDA $5.3M), it increases fixed obligations and limits financial flexibility compared to an all-equity deal.

• Overview: Organigram Global Inc. is a Canadian cannabis company transitioning into a global player with a focus on medical and recreational markets in Canada, Europe (Germany, Switzerland), and the U.S. hemp-derived THC sector.
• Flagship Project: The acquisition of Sanity Group GmbH serves as the primary growth engine for international expansion. It provides a vertically integrated hub in Germany (second-largest legal market) and access to Swiss retail pilots.
• Domestic Operations: Core business remains in Canada with brands like SHRED, Hemplified, and Tasty's. Recent Q1 FY2026 results showed 46% gross revenue growth ($97.3M).
• Innovation: Proprietary FAST™ nanoemulsion technology for faster onset beverages (e.g., SHRED Shotz launched March 2026) and seed-based cultivation partnerships with Phylos Bioscience.